AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI ®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for ...
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI ® ...
The company raised full year adjusted EPS guidance to between $11.88 and $12.08 and expects total net revenues of approximately $60.5 billion. Updated product assumptions include Skyrizi global ...
NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results